Novavax's Updated 2024-2025 Nuvaxovid™ COVID-19 Vaccine Receives Authorization in the EU
Novavax announced that the European Commission has granted Marketing Authorization for its updated 2024-2025 Nuvaxovid™ COVID-19 Vaccine for individuals aged 12 and older in the European Union. The authorization follows a positive opinion from the EMA's Committee for Medicinal Products for Human Use. Non-clinical data showed the updated vaccine provides cross-reactivity against JN.1 and numerous JN.1 lineage viruses.
The vaccine is also authorized for use in the U.S. under an Emergency Use Authorization. Common adverse reactions include headache, nausea, muscle pain, joint pain, injection site tenderness, fatigue, and malaise. The vaccine is indicated for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years and older.
Novavax ha annunciato che la Commissione Europea ha concesso l'Autorizzazione alla Commercializzazione per il suo vaccino aggiornato Nuvaxovid™ contro il COVID-19 per individui di età pari o superiore ai 12 anni nell'Unione Europea. L'autorizzazione segue un parere positivo del Comitato per i Prodotti Medicinali per Uso Umano dell'EMA. I dati non clinici hanno dimostrato che il vaccino aggiornato fornisce una reattività incrociata contro il JN.1 e numerosi virus della lineage JN.1.
Il vaccino è anche autorizzato per l'uso negli Stati Uniti sotto un'Autorizzazione all'Uso in Emergenza. Le reazioni avverse comuni includono mal di testa, nausea, dolori muscolari, dolori articolari, tenerezza nel sito di iniezione, affaticamento e malessere. Il vaccino è indicato per l'immunizzazione attiva per prevenire il COVID-19 causato da SARS-CoV-2 in individui di 12 anni e oltre.
Novavax anunció que la Comisión Europea ha concedido la Autorización de Comercialización para su vacuna Nuvaxovid™ COVID-19 actualizada para personas de 12 años y mayores en la Unión Europea. La autorización sigue a una opinión positiva del Comité de Medicamentos de Uso Humano de la EMA. Los datos no clínicos mostraron que la vacuna actualizada proporciona reactividad cruzada contra el JN.1 y numerosos virus de la línea JN.1.
La vacuna también está autorizada para su uso en EE. UU. bajo una Autorización de Uso de Emergencia. Las reacciones adversas comunes incluyen dolor de cabeza, náuseas, dolor muscular, dolor en las articulaciones, sensibilidad en el sitio de inyección, fatiga y malestar. La vacuna está indicada para la inmunización activa para prevenir el COVID-19 causado por SARS-CoV-2 en personas de 12 años o más.
노바백스가 유럽연합(EU)에서 12세 이상 개인을 위한 업데이트된 2024-2025 Nuvaxovid™ COVID-19 백신에 대한 마케팅 승인을 유럽연합 집행위원회가 부여했다고 발표했습니다. 이 승인은 EMA의 인체사용 의약품 위원회의 긍정적인 의견을 따릅니다. 비임상 데이터는 업데이트된 백신이 JN.1 및 여러 JN.1 계통 바이러스에 대해 교차 반응성을 제공함을 보여주었습니다.
이 백신은 또한 미국에서 긴급 사용 승인 하에 사용이 허가되었습니다. 일반적인 부작용으로는 두통, 메스꺼움, 근육통, 관절통, 주사 부위 통증, 피로감, 불쾌감이 포함됩니다. 이 백신은 12세 이상 개인의 SARS-CoV-2로 인한 COVID-19 예방을 위한 능동 면역화에 사용됩니다.
Novavax a annoncé que la Commission européenne a accordé une autorisation de mise sur le marché pour son vaccin Nuvaxovid™ COVID-19 mis à jour pour les personnes âgées de 12 ans et plus dans l'Union européenne. Cette autorisation fait suite à un avis positif du Comité des médicaments à usage humain de l'EMA. Les données non cliniques ont montré que le vaccin mis à jour offre une réactivité croisée contre le JN.1 et de nombreux virus de la lignée JN.1.
Le vaccin est également autorisé pour une utilisation aux États-Unis sous une autorisation d'utilisation d'urgence. Les réactions indésirables courantes comprennent des maux de tête, des nausées, des douleurs musculaires, des douleurs articulaires, une sensibilité sur le site d'injection, de la fatigue et un malaise. Le vaccin est indiqué pour l'immunisation active afin de prévenir le COVID-19 causé par le SARS-CoV-2 chez les personnes de 12 ans et plus.
Novavax gab bekannt, dass die Europäische Kommission die Marktzulassung für seinen aktualisierten Nuvaxovid™ COVID-19-Impfstoff für Personen ab 12 Jahren in der Europäischen Union erteilt hat. Die Zulassung folgt einer positiven Stellungnahme des Ausschusses für Humanarzneimittel der EMA. Nicht-klinische Daten zeigten, dass der aktualisierte Impfstoff eine Kreuzreaktivität gegen JN.1 und zahlreiche Viren der JN.1-Linie bietet.
Der Impfstoff ist auch in den USA unter einer Notfallgenehmigung zugelassen. Zu den häufigen Nebenwirkungen gehören Kopfschmerzen, Übelkeit, Muskelschmerzen, Gelenkschmerzen, Schmerzen an der Injektionsstelle, Müdigkeit und Unwohlsein. Der Impfstoff ist zur aktiven Immunisierung zur Prävention von COVID-19 durch SARS-CoV-2 bei Personen ab 12 Jahren vorgesehen.
- Marketing Authorization granted for updated 2024-2025 Nuvaxovid™ COVID-19 Vaccine in the EU
- Vaccine shows cross-reactivity against JN.1 and numerous JN.1 lineage viruses
- Authorization for use in individuals aged 12 and older
- Also authorized for use in the U.S. under Emergency Use Authorization
- Potential risks of myocarditis and pericarditis following vaccine administration
- Possible limitations in vaccine effectiveness for all recipients
- Various adverse reactions reported, including injection site pain and fatigue
Insights
The authorization of Novavax's updated COVID-19 vaccine in the EU is a significant milestone for the company. This approval demonstrates the vaccine's ability to target newer variants, particularly the JN.1 lineage, which is important for ongoing pandemic management. The cross-reactivity against multiple JN.1 sub-variants suggests broad protection, potentially enhancing the vaccine's appeal in a competitive market.
From an investor perspective, this authorization could lead to increased revenue streams for Novavax in the EU market. However, it's important to note that the vaccine landscape remains competitive, with mRNA vaccines still dominating. Novavax's protein-based approach might appeal to those seeking alternatives, but market penetration will depend on distribution capabilities and public health recommendations.
The alignment with FDA, EMA and WHO guidance on targeting JN.1 lineage positions Novavax favorably for potential global contracts. Investors should monitor uptake rates and any post-authorization safety data as key indicators of the vaccine's long-term market potential.
Novavax's EU authorization for its updated COVID-19 vaccine is a positive development for the company's financial outlook. With a market cap of
Key financial considerations include:
- Potential revenue boost from EU sales, which could improve Novavax's cash position
- Reduced R&D expenses as the vaccine moves from development to commercialization
- Possible economies of scale in production as demand increases
However, investors should be cautious about overestimating impact. The COVID-19 vaccine market is maturing, with potentially lower margins than in previous years. Novavax's ability to capture market share from established mRNA vaccines will be important for financial performance.
Monitor upcoming quarterly reports for concrete evidence of how this authorization translates into revenue growth and profitability. The company's cash burn rate and ability to secure additional contracts will be key metrics to watch.
Authorization was based on non-clinical data that showed Novavax's updated vaccine provides cross-reactivity against JN.1 and numerous JN.1 lineage viruses, including KP.2.3, KP.3, KP.3.1.1 and LB.1.1 In clinical trials, the most common adverse reactions associated with Novavax's prototype COVID-19 vaccine (NVX-CoV2373) included headache, nausea or vomiting, muscle pain, joint pain, injection site tenderness, injection site pain, fatigue and malaise.
Novavax's vaccine is also authorized for use in the
AUTHORIZED USE IN THE
Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) has not been approved or licensed by the FDA but has been authorized for emergency use by the FDA, under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older. Refer to the full Fact Sheet for information about the Novavax COVID-19 Vaccine, Adjuvanted.
The EUA of this product will remain in effect for the duration of the COVID-19 EUA declaration justifying emergency use of the product, unless the authorization is revoked sooner.
VACCINE AUTHORIZATION (
Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) is indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 years of age and older.
IMPORTANT SAFETY INFORMATION
Contraindications
- Do not administer the Novavax COVID-19 Vaccine, Adjuvanted to individuals with a known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the Novavax COVID-19 Vaccine, Adjuvanted.
Warnings and Precautions
- Management of Acute Allergic Reactions: Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of the Novavax COVID-19 Vaccine, Adjuvanted.
- Myocarditis and Pericarditis: Clinical trials data provide evidence for increased risks of myocarditis and pericarditis following administration of Novavax COVID-19 Vaccine, Adjuvanted.
- Syncope (fainting): may occur in association with administration of injectable vaccines. Procedures should be in place to avoid injury from fainting.
- Altered Immunocompetence: Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Novavax COVID-19 Vaccine, Adjuvanted.
- Limitations of Vaccine Effectiveness: The Novavax COVID-19 Vaccine, Adjuvanted may not protect all vaccine recipients.
Adverse Reactions
Solicited adverse reactions included: Injection site pain/tenderness, fatigue/malaise, muscle pain, headache, joint pain, nausea/vomiting, injection site redness, injection site swelling and fever.
Reporting Adverse Events and Vaccine Administration Errors
The vaccination provider is responsible for mandatory reporting of certain adverse events to the Vaccine Adverse Event Reporting System (VAERS) online at https://vaers.hhs.gov/reportevent.html, by calling 1-800-822-7967 or send an email to info@vaers.org.
About the Novavax COVID-19 2024-2025 Formula (NVX-CoV2705)
NVX-CoV2705 is an updated version of Novavax's prototype COVID-19 vaccine formulated to target the JN.1 variant. It is a protein-based vaccine made by creating copies of the surface spike protein of SARS-CoV-2 that causes COVID-19. With Novavax's unique recombinant nanoparticle technology, the non-infectious spike protein serves as the antigen that primes the immune system to recognize the virus, while Novavax's Matrix-M adjuvant enhances and broadens the immune response. The vaccine is packaged as a ready-to-use liquid formulation and is stored at 2° to 8°C, enabling the use of existing vaccine supply and cold chain channels.
About Matrix-M™ Adjuvant
When added to vaccines, Novavax's patented saponin-based Matrix-M adjuvant enhances the immune system response, making it broader and more durable.3 The Matrix-M adjuvant stimulates the entry of antigen-presenting cells at the injection site and enhances antigen presentation in local lymph nodes.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in
Forward-Looking Statements
Statements herein relating to the future of Novavax, its operating plans and prospects, the immunogenic response of its vaccine technology against variant strains including JN.1 lineage viruses, and the scope, timing and outcome of future regulatory filings and actions, including any EMA or FDA recommendations, the expectation to have unit dose vials available in select European countries this fall season, are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, antigenic drift or shift in the SARS-CoV-2 spike protein, challenges satisfying, alone or together with partners, various safety, efficacy and product characterization requirements, including those related to process qualification and assay validation, necessary to satisfy applicable regulatory authorities; difficulty obtaining scarce raw materials and supplies; resource constraints, including human capital and manufacturing capacity, on the ability of Novavax to pursue planned regulatory pathways; challenges or delays in obtaining regulatory authorization for a JN.1 protein-based COVID-19 vaccine or for future COVID-19 variant strain changes; challenges or delays in clinical trials; manufacturing, distribution or export delays or challenges; Novavax's exclusive dependence on Serum Institute of India Pvt. Ltd. for co-formulation and filling and the impact of any delays or disruptions in their operations on the delivery of customer orders; and those other risk factors identified in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Novavax's Annual Report on Form 10-K for the year ended December 31, 2023, and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov and www.novavax.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
Contacts:
Investors
Luis Sanay, CFA
240-268-2022
ir@novavax.com
Media
Giovanna Chandler
240-720-7804
media@novavax.com
References
- Kaku Y, Uriu K, Okumura K; Genotype to Phenotype Japan (G2P-
Japan ) Consortium, Ito J, Sato K. Virological characteristics of the SARS-CoV-2 KP.3.1.1 variant. Lancet Infect Dis. 2024;24(10):e609. doi:10.1016/S1473-3099(24)00505-X U.S. Centers for Disease Control and Prevention. Interim Clinical Considerations for Use of COVID-19 Vaccines inthe United States . September 6, 2024. Available at: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html.U.S. Centers for Disease Control and Prevention. CDC Recommends Updated 2024-2025 COVID-19 and Flu Vaccines for Fall/Winter Virus Season. June 27, 2024. Available at: https://www.cdc.gov/media/releases/2024/s-t0627-vaccine-recommendations.html.- World Health Organization. Statement on the antigen composition of COVID-19 vaccines. April 26, 2024. Available at: https://www.who.int/news/item/26-04-2024-statement-on-the-antigen-composition-of-covid-19-vaccines.
- European Medicines Agency. ETF recommends updating COVID-19 vaccines to target new JN.1 variant. April 30, 2024. Available at: https://www.ema.europa.eu/en/news/etf-recommends-updating-covid-19-vaccines-target-new-jn1-variant.
View original content to download multimedia:https://www.prnewswire.com/news-releases/novavaxs-updated-2024-2025-nuvaxovid-covid-19-vaccine-receives-authorization-in-the-eu-302270798.html
SOURCE Novavax, Inc.
FAQ
What is the new authorization for Novavax's COVID-19 vaccine (NVAX) in the EU?
What viruses does Novavax's updated COVID-19 vaccine (NVAX) show cross-reactivity against?
What are the common side effects of Novavax's COVID-19 vaccine (NVAX)?
Is Novavax's updated COVID-19 vaccine (NVAX) authorized in the United States?
